From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB.

Looking at this problem, the researchers conducted a randomized study to compare outcomes between 36 vs. 18 months of AB in men with high risk prostate cancer who are also treated with RT (PCS IV trial, Clinical Trials.gov, #NCT00223171).

In the trial they randomized menwith node negative high risk prostate cancer (T3-